- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02759484
Multi-clinic Action Trial to Control Hyperglycemia and Hypertension (MATCH2)
MATCH2: The Multi-clinic Action Trial to Control Hyperglycemia and Hypertension
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
MATCH2, a randomized controlled trial, will test if the optimized CHW-delivered intervention can reduce both Hemoglobin A1c levels and blood pressure at eighteen months in persons with uncontrolled diabetes, as compared to a CDE-delivered group educational program. Follow-up six months after the completion of the intervention will evaluate the sustainability of any gains. MATCH2 will use precise measures of diet (food frequency questionnaires) and physical activity (accelerometry) to identify intermediate behaviors and processes that mediate significant improvements in glycemic and blood pressure control.
Patients/participants will be recruited from three participating urban primary care safety net clinics to join MATCH2 if patients meet the inclusion and exclusion conditions (see criteria section below). Eligible patients interested in participation will have a baseline visit scheduled. Baseline assessments may be conducted either at the clinic, the participant's home, or the Rush Prevention Center, at the patient's preference. At the baseline visit, the research assistant will obtain informed consent for the study as approved by the Institutional Review Boards (IRB) of participating institutions. The baseline assessment will include the following measures: demographics, clinical data, glycemic control, blood pressure, total caloric and sodium intake, physical activity, medication adherence, clinic attendance, quality of life, patient activation, depression and social support.
A randomization scheme based on permuted randomized blocks of size 4 and 6 will be used, stratified by clinic. Randomization schedules will be developed by the study Biostatistician and the Data Management Team will assign participants to treatment or control groups accordingly.Of the investigative team, the Principal Investigator, identified Key Co-Investigators and all research assistants will be blinded to the patient's group assignment while remaining research team: the Community Health Workers (blinded to study hypothesis), selected Key Co-Investigators, Site Principal Investigators, and Data Management Team will be unblinded.
Participants will know the study condition to which participants have been assigned. As with the CHW interventionists, participants will be blinded to the study hypothesis. Consent and recruitment forms will all state that "The MATCH2 trial is comparing two clinic-based approaches to improve control of high blood sugar and high blood pressure in people with type 2 diabetes. Some evidence suggests that approaches such as health classes led by a diabetes educator, coaching by Community Health Workers, and printed diabetes education materials may help improve outcomes for people with uncontrolled diabetes.
ENHANCED HOME-BASED EDUCATION CONDITION: CHW Interventionists deliver diabetes self-management curriculum in the participant's home or other preferred setting.
MATCH2 Trained CHW Interventionists will work closely with patients to deliver a participant-centered intervention derived from two pragmatic evidence-based frameworks for behavioral change [Motivational Interviewing (MI) and Kate Lorig's Chronic Disease Self-Management approach]. 24 total in-person visits will be conducted; six primary topics will be covered multiple times over an 18-month period. No more than two topics will be addressed at any visit. The sequence in which topics are delivered is determined by participant need, preference, and interest. The six primary topics are:
- Check glucose daily and know the goal.
- Check blood pressure daily and know the goal.
- Understand medications and take medications as prescribed.
- Engage in 30 minutes of physical activity every day.
- Enjoy a healthy natural diet with vegetables, fruit, and fiber.
- Communicate any concerns to the health care team.
At each visit, CHWs will help participants develop a self-management Action Plan around one of the six topics, and support problem solving behaviors to address barriers to completing the Action Plan. Behavioral self-management skills will be taught by the CHW and practiced with the participant at each visit. CHWs will monitor the clinic attendance of participants and will advise and assist participants with making appointments with their primary care providers at least once every 4 months. CHWs will also play an active role in communicating the progress of their participants to the primary care providers using the clinic Electronic Medical Record.
ENHANCED CLINIC-BASED EDUCATION CONDITION: Participants will receive group diabetes self-management education, consistent with current Medicare guidelines for diabetes education. A Certified Diabetes Educator will deliver the two class sessions (each two hours) covering basic topics: diabetes (including self-management) and nutrition. Participants will also receive 24 bilingual educational newsletters: twelve during the first six months and then once a month between 6 and 18 months. The newsletters, called "Diabetes Action", cover the same six self-management topics listed previously.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Illinois
-
Chicago, Illinois, United States, 60622
- Erie Family Health Center
-
Chicago, Illinois, United States, 60612
- Rush University Internists
-
Cicero, Illinois, United States, 60804
- Cicero Health Center of Cook County
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Diagnosis of type 2 diabetes mellitus with A1c greater than or equal to 7.0
- At least 18 years of age and capable of giving informed consent in either English or Spanish
- Primary care received through a participating clinic
- Participants must identify themselves as either Black / African American race or Hispanic / Latino ethnicity
Exclusion Criteria:
- Have end-stage renal disease, stroke, or other major end-organ complication of diabetes
- Require chronic prednisone or other systemic corticosteroid use
- Are receiving treatment for a major psychiatric disorder (i.e. schizophrenia)
- Live in a household with someone who is already a randomized study participant
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Home Based Enhanced Education
The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
|
The Home Based Enhanced Education arm consists of a diabetes self-management curriculum delivered by Community Health Workers in the participant's home.
Participants receive 24 visits: 12 biweekly visits in the first 6 months, followed by 12 monthly visits in months 6 through 18 of the study.
The self-management program is derived from two pragmatic evidence-based frameworks for behavioral change.
Other Names:
|
|
Active Comparator: Clinic Based Enhanced Education
The Clinic Based Enhanced Education arm consists of group diabetes self-management education, delivered by a Certified Diabetes Educator, plus mailed diabetes self-management education.
|
The Clinic Based Enhanced Education arm consists of two two-hour-long sessions of group diabetes self-management education, delivered by a Certified Diabetes Educator.
Participants in this arm will also receive 24 newsletters with diabetes self-management education.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Glycemic Control
Time Frame: Up to 18 months post randomization
|
Glycemic control will be determined by Hemoglobin A1c, measured on a fingerstick collected Dried Blood Spot test, and analyzed by an independent reference lab.
|
Up to 18 months post randomization
|
|
Blood Pressure Control
Time Frame: Up to 18 months post randomization
|
Blood Pressure (BP) will be measured three times using an automated blood pressure cuff with the participant in a seated position.
Mean Arterial Pressure will be calculated by the standard formula: Diastolic BP + 1/3 (Systolic BP - Diastolic BP)] .
|
Up to 18 months post randomization
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Maintenance of Glycemic Control
Time Frame: Up to 24 months post randomization
|
Glycemic control will be determined by Hemoglobin A1c, measured on a fingerstick collected Dried Blood Spot test, and analyzed by an independent reference lab.
|
Up to 24 months post randomization
|
|
Maintenance of Blood Pressure Control
Time Frame: Up to 24 months post randomization
|
Blood Pressure (BP) will be measured three times using an automated blood pressure cuff with the participant in a seated position.
Mean Arterial Pressure will be calculated by the standard formula: Diastolic BP + 1/3 (Systolic BP - Diastolic BP)] .
|
Up to 24 months post randomization
|
|
Intermediate Behavior: Dietary Adherence
Time Frame: Up to 18 months
|
Repeated 24-hour dietary recalls using the Nutrition Data System for Research (NDSR)
|
Up to 18 months
|
|
Intermediate Behavior: Physical Activity
Time Frame: Up to 18 months
|
Accelerometer, worn for one week.
|
Up to 18 months
|
|
Intermediate Behavior: Medication Adherence
Time Frame: Up to 18 months
|
Morisky 8-item questionnaire (MMAS-8)
|
Up to 18 months
|
Other Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Intervention Costs
Time Frame: Up to 24 months
|
Participant and system costs will be collected including, but not limited to: all intervention costs, participant time and travel, clinic visits, emergency department encounters, hospitalizations, and medication costs.
|
Up to 24 months
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Steven K Rothschild, MD, Rush University Medical Center
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 12052906
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Mellitus, Type 2
-
University of North Carolina, Chapel HillAmerican Heart AssociationRecruitingType 2 Diabetes | Nutrition | Diabetes Type 2 | T2DM (Type 2 Diabetes Mellitus) | Diabetes Mellitis | T2DM | Diabetes EducationUnited States
-
Instituto Nacional de Ciencias Medicas y Nutricion...Active, not recruiting
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes Mellitus | Type 2 Diabetes | Type2diabetes
-
University of SalamancaUniversity of Salamanca; Instituto Piaget; Escola Superior de Tecnologia da Saúde...Enrolling by invitationType 2 Diabetes Mellitus | Aging | Hyperglycemia Due to Type 2 Diabetes MellitusPortugal
-
Endogenex, Inc.Not yet recruitingDiabetes Mellitus, Type 2 | Diabetes | Type 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type2Diabetes
-
University of Colorado, DenverMassachusetts General Hospital; Ann & Robert H Lurie Children's Hospital of... and other collaboratorsRecruitingDiabetes Mellitus | Diabetes | Type 2 Diabetes | Diabetes Mellitus Type 2 | Diabetes Mellitus, Type I | Diabetes Mellitus Type II | Diabetes Mellitus, Insulin-Dependent | Diabetes, Autoimmune | Type 1 Diabetes (T1D) | Diabetes Type 2 on Insulin | Diabetes, Type IIUnited States
-
Kaiser PermanenteThe Permanente Medical GroupEnrolling by invitationType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes (T2D)United States
-
Medical University of GrazCompletedType 2 Diabetes | Type 2 Diabetes Mellitus (T2DM) | Type 2 Diabetes, Insulin RequiringAustria
-
SanofiCompletedType 1 Diabetes Mellitus-Type 2 Diabetes MellitusHungary, Russian Federation, Germany, Poland, Japan, United States, Finland
-
Canterbury Christ Church UniversityBarts & The London NHS Trust; Betsi Cadwaladr University Health BoardRecruitingType 1 Diabetes Mellitus | Type 2 Diabetes Mellitus (T2DM)United Kingdom
Clinical Trials on Home Based Enhanced Education
-
University of Southern CaliforniaPatient-Centered Outcomes Research InstituteTerminatedCancer | Chronic Obstructive Pulmonary Disease | Congestive Heart FailureUnited States
-
Assistance Publique - Hôpitaux de ParisCentre Leon Berard; Ministry of Health, France; Université Montpellier; Telecom... and other collaboratorsUnknownKidney Transplantation | End-stage Renal Disease | Dialysis
-
Hospital de Clinicas de Porto AlegreFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, BrazilCompleted
-
Hasan Kalyoncu UniversityCompletedLiver Transplantation | Fatigue | Physical InactivityTurkey (Türkiye)
-
Johns Hopkins UniversityCompleted
-
University of PittsburghNational Institute of Nursing Research (NINR)CompletedExercise | Lung TransplantationUnited States
-
University of Illinois at Urbana-ChampaignCompletedMultiple Sclerosis | Adult DiseaseUnited States
-
Cairo UniversityCompletedCerebral Palsy (CP) | Tele-rehabilitationEgypt
-
Hospital de Clinicas de Porto AlegreFundação de Amparo à Pesquisa do Estado do Rio Grande do Sul, BrazilCompleted
-
Nova Scotia Health AuthorityCanadian Orthopaedic FoundationCompletedTotal Hip ArthroplastyCanada